| Literature DB >> 34519329 |
Khaloud M Alarjani1, Manal F Elkhadragy2, Abdulrahman H Al-Masoud3, Hany M Yehia3,4.
Abstract
Campylobacter jejuni and Salmonella typhimurium are the leading causes of bacterial food contamination in chicken carcasses. Contamination is particularly associated with the slaughtering process. The present study isolated C. jejuni and S. typhimurim from fifty chicken carcass samples, all of which were acquired from different companies in Riyadh, Saudi Arabia. The identification of C. jejuni was performed phenotypically by using a hippurate test and genetically using a polymerase chain reaction with primers for 16S rRNA and hippurate hydrolase (hipO gene). For the dentification of S. typhimurim, a serological Widal test was carried out using serum anti-S. typhimurium antibodies. Strains were genetically detected using invA gene primers. The positive isolates for C. jejuni showed a specific molecular size of 1448 bp for 16S rRNA and 1148 bp for hipO genes. However, the positive isolates of the invA gene exhibited a specific molecular size at 244 bp using polymerase chain reaction (PCR). Comparing sequencing was performed with respect to the invA gene and the BLAST nucleotide isolates that were identified as Salmonella enterica subsp. enterica serovar typhimurium strain ST45, thereby producing a similarity of 100%. The testing identified C.jejuni for hippuricase, GenBank: Z36940.1. While many isolates of Salmonella spp. that contained the invA gene were not necessarily identified as S. typhimurim, the limiting factor for the Widal test used antiS. typhimurum antibodies. The multidrug resistance (MDR) of C. jejuni isolates in chickens was compared with the standard C. jejuni strain ATCC 22931. Similarly, S. typhimurium isolates were compared with the standard S. typhimurium strain ATCC 14028.Entities:
Keywords: Campylobacter jejuni; Hipo gene; Salmonella typhimurim; chicken carcass; invA gene; multidrug resistance
Mesh:
Substances:
Year: 2021 PMID: 34519329 PMCID: PMC8458795 DOI: 10.1042/BSR20211790
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Figure 1Colonies of C. jejuni
Colonies on Campylobacter blood-free selective agar (modified CCDA-preston) (A) and on Bolton selective enrichment agar with agar supplements and with 25 ml of horse blood (B), creating a gram-negative spiral shape when stained with Gram stain (C).
Figure 2Hippurate hydrolysis test
For C. jejuni ATCC 33291 (+) and C. coli ATCC 33559 (-).
Figure 3PCR amplification of 16S rRNA and hipO gene primers of C. jejuni isolates
Results for Salmonella sp., invA gene, and serum antityphimurium and C. jejuni isolate detection in chicken samples
| Microorganisms |
| Sequence identification |
| Sequence identification | |||||
|---|---|---|---|---|---|---|---|---|---|
| Poultry companies | No. of samples | No. of isolates |
| Widal test | No. of isolates |
| 16S rRNA | ||
|
| 10 | 7 | 5 | 2 | 1 | 1 | 1 | ||
|
| 10 | 6 | 4 | 0 | 2 | 1 | 1 | ||
|
| 10 | 9 | 5 | 2 | 2 | 1 | 1 | ||
|
| 10 | 6 | 6 | 4 | 3 | 1 | 1 | ||
|
| 10 | 5 | 3 | 2 | 1 | 1 | 1 | ||
|
| 50 | 33 | 23 | 10 | 10 | 9 | 5 | 5 | 5 |
|
| 100 | 66 | 69.69 | 43.47 | 43.47 | 18 | 55.55 | 55.55 | 55.55 |
Figure 4PCR amplification of S. typhimurium invA gene primers
Positive invA gene amplification for S. typhimurium ATCC 14028 and S. enetritidis ATCC 13076 (Lane 1 and Lane 2) for 21 isolates (3-10), (11-18), (20) and (23-26). The DNA band at 244 bp shows marker presence, as visualized by gel electrophoresis using 1% agarose with an image analyser (SYNGENE) and DNA marker (1 kb ladder)
The susceptibility test for C. jejuni isolates
| Antibiotics classes | β- Lactam | Chloramphenicol | Quinolones | Oxazolidone | Aminoglycosides | Lipopeptides | Penicillin | Glycopeptide | Tetracyclines | Macrolides | % | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Isolates | AMC 30 ≥18 14-17 ≤13 | C 30 ≥ 1 8 13-17 ≤12 | CIP 5 ≥ 2116-20≤ 15 | NA 30 ≥ 1914-18 ≤13 | LZD 30 ≥ 21 – ≤ 20 | K 30 ≥ 18 14-17 ≤13 | N 30 ≥ 16 14-17 ≤12 | CT 25 ND | TIC 75 ≥20 15-19 ≤14 | AMP 25 ≥ 17-14-16 ≤ 13 | VA 5 ≥ 17 15-16 ≤ 14 | DO 30 ≥ 14 11-13 ≤ 10 | E 15 ≥ 23 14-22 ≤13 | F300 ≥ 1 7 15-16 ≤14 | Resistance | Intermediate | Sensitivity |
| R | S | I | S | R | S |
| R | I | R | R | R | R | R | 57.15 | 14.28 | 28.57 | |
| R | R | R | R | R | R |
| R | R | R | R | R | R | R | 100 | 0 | 0 | |
| R | R | R | I | R | R |
| R | R | R | R | R | I | R | 85.71 | 14.28 | 0 | |
| R | R | R | I | R | R |
| R | R | R | R | R | R | S | 85.71 | 7.14 | 7.14 | |
| R | R | I | I | R | R |
| R | R | R | R | R | R | S | 78.57 | 14.28 | 7.14 | |
| R | R | I | I | R | R |
| R | R | R | R | R | R | S | 78.57 | 14.28 | 7.14 | |
| R | S | R | R | R | I |
| R | R | R | R | R | R | S | 78.57 | 7.14 | 14.28 | |
| R | S | R | R | R | I |
| R | R | R | R | R | R | S | 78.57 | 7.14 | 14.28 | |
| R | S | R | R | R | I |
| R | R | R | R | R | R | S | 78.57 | 7.14 | 14.28 | |
| R | R | R | R | R | R |
| R | R | R | R | R | R | S | 92.8 | 7.14 | 0 | |
| Resistance % | 100 | 60 | 70 | 50 | 100 | 60 |
| 100 | 90 | 100 | 100 | 100 | 90 | 30 | - | - | - |
| Intermediate % | 0 | 0 | 30 | 40 | 0 | 30 |
| 0 | 10 | 0 | 0 | 0 | 10 | 0 | - | - | - |
| Sensitive % | 0 | 40 | 0 | 10 | 0 | 10 |
| 0 | 0 | 0 | 0 | 0 | 0 | 70 | |||
Mean zones of inhibition for common antibiotics: S = Sensitive, I = Intermediate, R = Resistant, except noted above and *ND = Not Detected: treated as a common antibiotic inhibition zone. AMC = Amoxy/clav.acid (30 μg), C 30 = Chloramphenicol (30 μg), CIP 5 = Ciprofloxacin (5 μg), LZD 30 = Linezolid (30 μg), K30 = Kanamycin (30 μg), N 30 = Neomycin (30 µg), CT 25 = Colistin sulfate (25 µg), TIC 75 = Ticarcillin (75 μg), AMP 25 = Ampicillin (25 μg), VA 30 = Vancomycin (30 µg), Do 30 = Doxycyclin (30 µg), E 15 = Erythromycin (15 μg), F 300 = Nitrofurantoin (300 μg).
The susceptibility test for S. typhimurium isolates
| Antibiotics classes | B-lactam | Aminoglycosides | Cyclicpeptides | Sulfonamide | Quinolone | Fluoroquinolone | Oxazolidone | Macrobid | Chloramphenicol | Glycopeptide | Lincosamide | % | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Isola- tes | R I S | FOX 30 ≥ 18 15-17 ≤14 | CAR 100 ND | TIC 75 ≥20 15-19 ≤14 | AMC 30 ≥18 14-17 ≤13 | CTX 30 ≥ 26 23-25 ≤22 | S 10 ≥ 15 12-14 ≤11 | CN 10 ≥ 15 13-14 ≤12 | K 30 ≥ 18 14-17 ≤13 | N 30 ≥ 16 14-17 ≤12 | TE 30 ≥ 15 13-15 ≤ 4 | RL 25 ND* | NA 30 ≥ 19 14-18 ≤13 | NOR 5 ≥ 17 13-16 ≤12 | OFX 5 ≥ 1 6 13-15 ≤12 | LZD 30 ≥ 21 — ≤10 | F 300 ≥ 1 7 15-16 ≤14 | E 15 5 ≥ 23 14-22 ≤13 | C 30 ≥ 1 8 13-17 ≤12 | VA 30 ≥ 17 15-16 ≤ 14 | MY 2 ND* | Resistance | Intermediate | Sensitive |
|
| R | R | S | S | S | R | S | I | R | S | R | S | S | S | R | I | R | S | R | R | 45 | 10 | 45 | |
|
| R | R | I | S | S | R | S | I | I | R | R | S | S | S | R | I | R | S | R | R | 45 | 20 | 35 | |
|
| R | R | I | S | S | R | S | I | I | S | R | R | S | S | R | I | R | S | R | R | 45 | 20 | 35 | |
|
| R | R | I | S | S | R | S | I | I | S | R | R | S | S | S | I | R | S | R | R | 40 | 20 | 35 | |
|
| R | R | R | S | S | R | S | I | I | R | R | S | S | S | R | I | R | S | R | R | 50 | 15 | 35 | |
|
| R | R | I | S | S | R | S | I | R | R | R | S | S | S | S | R | R | R | R | R | 55 | 10 | 35 | |
|
| R | R | R | S | S | R | S | I | I | R | R | R | S | S | R | R | R | S | R | R | 60 | 5 | 35 | |
|
| R | R | I | S | S | R | S | I | R | S | R | R | S | S | R | I | R | S | R | R | 50 | 10 | 35 | |
|
| R | R | R | S | S | R | S | I | R | R | R | R | S | S | R | I | R | S | R | R | 60 | 10 | 30 | |
|
| R | R | R | S | S | R | S | I | R | S | R | R | S | S | R | I | R | S | R | R | 55 | 5 | 35 | |
| Resistance % | 100 | 100 | 40 | 0 | 0 | 100 | 0 | 0 | 60 | 50 | 100 | 40 | 0 | 0 | 100 | 20 | 100 | 0 | 100 | 100 | - | - | - | |
| Intermediate % | 0 | 0 | 50 | 0 | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 60 | 100 | 0 | 0 | 80 | 0 | 0 | 0 | 0 | - | - | - | |
| Sensitive % | 0 | 0 | 10 | 100 | 100 | 0 | 100 | 0 | 40 | 50 | 0 | 0 | 0 | 100 | 0 | 0 | 00 | 100 | 0 | 0 | - | - | - | |
Mean zones of inhibition for common antibiotics: S = Sensitive, I = Intermediate, R = Resistant, except noted above and *ND = Not Detected: treated as a c100ommon antibiotic inhibition zone. FOX = Cefoxitin (30 μg), CAR = Carbenicillin 100 µg, TIC 75 = Ticarcillin (75 μg), AMC = Amoxy/clav.acid (30 μg), CTX = Cefotaxime 30 µg, S = Streptomycin (100 μg), CN = Gentamycin (10 µg), K30 = Kanamycin (30 μg), N = Neomycin (30 µg), TE = Tetracycline (30 μg), RL = Sulfamethoxazole (25 μg), NA = Naldioxic acid (30 μg), NOR = Norfloxacin (5 µg), OFX = Ofloxacin (5 µg), LZD 30 = Linezolid (30 μg), F 300 = Nitrofurantoin (300 μg), E 15 = Erythromycin (15 μg), C 30 = Chloramphenicol (30 μg), VA 30 = Vancomycin (30 µg). MY = Lincomycin (2 µg)
Figure 5Whole protein profiles of S. typhimurium isolates by SDS/PAGE
Lane M molecular weight standard. Lane 2 S. typhimurium ATCC 14028, Lanes 3–10 S. typhimurium total protein and a positive antisera typhimurium.